Prosecution Insights
Last updated: April 19, 2026
Application No. 18/322,680

PROCESS FOR PREPARING CONJUGATED DIENE COMPOUND UTILIZING INTRAMOLECULAR SIGMATROPIC REARRANGEMENT REACTION

Non-Final OA §102
Filed
May 24, 2023
Examiner
TESKIN, FRED M
Art Unit
1762
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Shin-Etsu Chemical Co. Ltd.
OA Round
1 (Non-Final)
90%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
97%
With Interview

Examiner Intelligence

Grants 90% — above average
90%
Career Allow Rate
1176 granted / 1313 resolved
+24.6% vs TC avg
Moderate +8% lift
Without
With
+7.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
34 currently pending
Career history
1347
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
38.7%
-1.3% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
27.6%
-12.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1313 resolved cases

Office Action

§102
DETAILED ACTION Status of Application This action is responsive to nonprovisional application filed 05/24/2023. Original claims 1-3 are currently pending and under examination herein. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . However, in the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for a rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Information Disclosure Statement(s) The information disclosure statement(s) (IDS) filed on 05/24/2023 and 09/03/2025 are in compliance with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609, and therefore the information referred to therein has been considered as to the merits. Initialed copies of the IDS are included with the mailing/transmittal of this Office action. Foreign Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Claim Rejections – 35 U.S.C. 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 3 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Rondan et al (Tetrahedron Letters, Vol. 25, No. 24, 2519-2522, 1984) (‘Rondan’). Regarding Claims 1 and 3, Rondan has already described the thermal sigmatropic isomerization of 1,3-pentadiene via 1,5-hydrogen shifts as depicted in the formulation below: PNG media_image1.png 112 461 media_image1.png Greyscale (pp. 2519-2520) In the depicted scheme, the structure at the left-hand side is seen to correspond to the Applicant’s conjugated diene compound (2) of general formula (2), where Z is a methyl group, m is 0 and n is 1, while the structure at the right-hand side corresponds to the Applicant’ conjugated compound (4) of general formula (4) where Z is as defined above, m+1=1 and n-1=0. As such, Rondan is considered to fully describe the claimed process for preparing a conjugated diene compound where a conjugated diene compound (2) of the general formula (2) is subjected to an intramolecular sigmatropic rearrangement reaction to obtain a conjugated diene compound (4) of the general formula (4). Claims 1 and 2 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by O’Neal et al (J. of Chem. Kinetics, Vol. 11: 343-347 (1970)) (‘O’Neal’). Regarding Claims 1 and 2, O’Neal has already described the thermal isomerization of cis-hepta-1,3-diene via a 1,5-hydrogen shift as proceeding almost stereospecifically to cis-2-trans-4-heptadiene as shown below: PNG media_image2.png 68 169 media_image2.png Greyscale (pp. 344-347 (Tables I, II)) The cis-1,3 diene structure is seen to correspond to the Applicant’s conjugated diene compound (1) of general formula (1), where Z is a methyl group, n is 0 and m is 3, while the cis-2-trans-4 diene structure corresponds to the Applicant’ conjugated compound (3) of general formula (3) where Z is as defined above and n+1=1 and m-1=2. While O’Neal does not explicitly refer to the described thermal isomerization as a sigmatropic rearrangement reaction, the reaction depicted above clearly involves an intramolecular rearrangement and is carried out at a temperature of ~ 100oC (see p. 344, 2nd full para), this heating temperature being well within the Applicant’s preferred reaction temperature range at which the instant reaction is said to proceed (cf., Spec., [0017]). As such, O’Neal is considered to implicitly describe the claimed process comprising: subjecting to an intramolecular sigmatropic rearrangement reaction, a conjugated diene compound (1) of the general formula (1) to obtain a conjugated diene compound (3) of the general formula (3). Conclusion Claims 1-3 are rejected. No claims are in condition for allowance at this time. Correspondence Any inquiry concerning this communication should be directed to Examiner F. M. Teskin whose telephone number is (571) 272-1116. The examiner can normally be reached on Monday through Friday from 9:00 AM - 5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Jones, can be reached at (571) 270-7733. The appropriate fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. /FRED M TESKIN/Primary Examiner, Art Unit 1762 /FMTeskin/01-10-26
Read full office action

Prosecution Timeline

May 24, 2023
Application Filed
Jan 10, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600831
LATEX HYPERBRANCHED ANION EXCHANGERS
2y 5m to grant Granted Apr 14, 2026
Patent 12599887
Loop Slurry Reactor Cooling Processes and Systems
2y 5m to grant Granted Apr 14, 2026
Patent 12595330
Polyolefin-Polystyrene-Based Multiblock Copolymer and Method for Preparing the Same
2y 5m to grant Granted Apr 07, 2026
Patent 12590179
COPOLYMERS AND TERPOLYMERS OF POST MODIFIED POLYACRYLATES AS EFFICIENT GAS HYDRATE INHIBITORS
2y 5m to grant Granted Mar 31, 2026
Patent 12590409
ACRYLATE OLIGOMERS, ACRYLATE OLIGOMER EMULSIONS, AND FLUORINE-FREE STAIN-RELEASE COMPOSITIONS CONTAINING THE SAME
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
90%
Grant Probability
97%
With Interview (+7.8%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 1313 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month